ELAB.US Exchange offer

Elevai Labs Inc. (ELAB.US) announced an offer to exchange outstanding shares of common stock of Elevai Labs Inc. Holders who exchange will receive 1 share of Series B Preferred Stock for each share of Common stock surrendered. Subject to Proration. Participants should obtain the Offer to Exchange dated 05/11/2024 for complete details of the offer. Participants should consult their tax advisor for complete details in reference to withholding taxes.

The shares of the Series B Preferred Stock are Restricted and Non-Tradeable. A stockholder who desires to tender Common Stock in the Offer must tender all of
such stockholders Common Stock.

The terms of the offer are as follows:

Option (1) : Take no action [Default Option]

Option (2): EXCHANGE SHARES - 1 share of Elevai Labs Inc. for 1 share of Series B Preferred Stock

The deadline to tender shares to the offer will be 20/11/2024@ 16:00 (HONG KONG TIME GMT+8).

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number:
2. Name: (In Chinese or English)
3. Stock code: ELAB.US
4. Options: (1) or (2)
5. Number of shares participating in corporate actions:

Note to applicants:
1. For shareholders holding less than 1 share of ELAB.US, they cannot participate in related corporate actions.
2. Option (1) is the default option. We will help clients to choose option (1) if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7. If there is any update, all the information released by the listed company shall prevail.

Helpful？

Yes No